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Abstract
In this paper, we develop a general Bayesian hierarchical model for bridging across patient subgroups in phase I oncology
trials, for which preliminary information about the dose–toxicity relationship can be drawn from animal studies.
Parameters that re-scale the doses to adjust for intrinsic differences in toxicity, either between animals and humans
or between human subgroups, are introduced to each dose–toxicity model. Appropriate priors are specified for these
scaling parameters, which capture the magnitude of uncertainty surrounding the animal-to-human translation and
bridging assumption. After mapping data onto a common, ‘average’ human dosing scale, human dose–toxicity parameters
are assumed to be exchangeable either with the standardised, animal study-specific parameters, or between themselves
across human subgroups. Random-effects distributions are distinguished by different covariance matrices that reflect the
between-study heterogeneity in animals and humans. Possibility of non-exchangeability is allowed to avoid inferences for
extreme subgroups being overly influenced by their complementary data. We illustrate the proposed approach with
hypothetical examples, and use simulation to compare the operating characteristics of trials analysed using our Bayesian
model with several alternatives. Numerical results show that the proposed approach yields robust inferences, even when
data from multiple sources are inconsistent and/or the bridging assumptions are incorrect.
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1 Introduction
Bridging strategies are increasingly being used in the paradigm of global drug development1–4 to minimise
duplication of clinical research without disregarding heterogeneity between patient groups. Bridging studies
may be conducted in a new geographic region to evaluate whether a medicine’s performance (typically efficacy)
is consistent with its performance in other parts of the world where it has been approved based on a complete
development program. The International Conference on Harmonisation (ICH) E5 Guideline5,6 discusses whether
and when trial data generated in an ‘original’ region can be leveraged to support the evaluation of drug activities
in a new region where a sponsor is seeking registration. The degree of borrowing, ranging from none to full, is a
matter of negotiation between the sponsor and the local health authority. By avoiding the unnecessary replication
of evidence, bridging strategies can mitigate the drug lag problem7–9 and expedite patient access to new medicines.
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Over the past few decades, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has promoted
synchronisation of clinical drug development in Japan and other countries.10 The agency encourages domestic
sponsors to participate in global phase I dose-finding studies in oncology, which has led to a number of early
phase bridging studies. It was further contended that phase I trials in Japan could be carried out in similar times as
those in the west, based on the finding of small between-region heterogeneity in the toxicity profile of single
agents, as 54 phase I oncology trials conducted at the National Cancer Center Hospital in Japan between 1995
and 2012 had been reviewed.11 In this paper, we will focus on the design and analysis of phase I bridging studies,
which aim to support estimation of the maximum tolerated dose (MTD) in a new geographic region or patient
subgroup of a previously studied disease indication. We want to leverage the dose–toxicity data available in
relevant, already studied populations, without neglecting possible heterogeneity stemming from intrinsic factors
such as a patient’s genetic make-up, and/or extrinsic factors such as diagnostic criteria and environmental
exposures. Wider application of the proposed Bayesian model can also include, for example, phase I trials eval-
uating the toxicity profile of a given treatment for multiple disease subtypes.
Several model-based designs have been proposed for phase I clinical trials to account for potentially different
safety profiles of a new medicine in various patient subgroups. Liu et al.12 develop a bridging continual reassess-
ment method (CRM) procedure that uses the dose–toxicity data from a completed historical trial to generate
multiple sets of ‘skeleton’ probabilities for a new trial in a different geographic region, with the most plausible set
of skeleton probabilities weighted favourably through the Bayesian model averaging.13 Takeda and Morita14
present a Bayesian dose-escalation procedure which dynamically leverages information from a historical study.
Specifically, before the new trial begins, historical trial data are used to formulate a weakly informative prior for
the parameter of a dose–toxicity model employed by the CRM for dose recommendations; so-called weakly
informative because the prior effective sample size15 is considerably smaller than the anticipated sample size of
the new trial. Historical and new trial data are then linked through a ‘historical-to-current’ parameter, which
reflects the degree of agreement between the studies.
Alternatively, relevant ‘complementary-data’ (or co-data for short)16 can be leveraged from phase I clinical
trials run concurrently with the trial of interest, or from commensurate patient subgroups enrolled in the same
trial. O’Quigley et al.17 propose a two-sample CRM to draw inferences about the MTD appropriate for each of
the two non-overlapping subgroups of patients. The dose–toxicity curves are modelled through a pair of param-
eters, one of which represents information common to both subgroups and the other, as a ‘shift parameter’, for
heterogeneity of the second subgroup in relation to the first. O’Quigley and Iasonos18 discuss theoretical prop-
erties of this bridging model when the shift parameter is discrete, allowing for the recommended dose in the second
subgroup to be one or two dose levels away from the estimate in the first. Wages et al.19 extend this CRM-type
shift model to account for uncertainty about the true shifts and design a phase I/II trial of stereotactic body
radiation therapy, where the dose–response relationship may present as non-monotonic.
To date, designs for phase I bridging studies have focused on co-data from trials conducted under similar
circumstances, for example, studies evaluating a different yet relevant patient subgroup. However, preliminary
data from animal toxicology studies will also be available, as is required by regulatory authorities.20 It is appealing
to use the animal and external human trial data, in addition to any human trial data from relevant patient
subgroups, so that dose recommendations at early stages of the phase I trial can be informed by all relevant
evidence.21,22 The challenge is to properly link the dose–toxicity models for different animal species and human
subgroups. In situations of strong differences between toxicity profiles, the co-data should be quickly discounted
from the analysis of the new phase I clinical trial.
Zheng et al.21 propose a robust Bayesian hierarchical model to leverage data from multiple animal species in a
phase I oncology trial which will be performed in a homogeneous patient group, to support the interim and final
dosing recommendations. In this paper, we extend their approach to accommodate the case that the study pop-
ulation is made of heterogeneous patient subgroups. The robust extention proposed in this paper can therefore
augment a phase I bridging trial with co-data, which may comprise (i) data from completed preclinical animal
studies and/or (ii) concurrent external data from either completed or ongoing trials conducted in related patient
subgroups (e.g. patients from other geographic regions). When the intrinsic and extrinsic factors arising from
ethnicity would result in heterogeneous dose–toxicity relationships, our model will estimate the subgroup-
specific MTDs.
The remainder of this paper is structured as follows. In Section 2, we develop a robust Bayesian hierarchical
random-effects model leveraging data from both animal studies and related human subgroups, to support the
analysis of a new phase I oncology trial. In Section 3, we illustrate the use of the proposed methodology for
improved decision making with various hypothetical data examples. In Section 4, we perform a simulation study
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to compare the operating characteristics of dose-escalation trials driven by the proposed model with several
alternatives. Finally, we draw conclusions and look towards future research in Section 5.
2 Bayesian hierarchical model for animal data and heterogeneous human data
In this section, we generalise the Bayesian model of Zheng et al.21 to leverage available animal data and dose–
toxicity data from different human subgroups into new phase I clinical studies.
Suppose that at the time of planning a phase I clinical trial, M preclinical studies have been performed in K
animal species, labelled S1; . . . ;SK. For i ¼ 1; . . . ;M, animal study i tested a total of Ji doses contained in set
Di ¼ fdi1; . . . ; diJi ; dit1  dit2 for 1  t1  t2  Jig. On receiving dose dij 2 Di, an animal experiences a dose-
limiting toxicity (DLT) with probability pij and no DLT with probability 1 pij. Let nij and rij be the number of
animals that received dose dij and the number that experienced a DLT, respectively. We assume a monotonic
increasing relationship between pij and dij, which can be adequately described by a two-parameter logistic regres-
sion model23,24
rijjpij; nijBinomialðpij; nijÞ; for j ¼ 1; . . . ; Ji;
logitðpijÞ ¼ h1i þ expðh2iÞlogðdAi dij=dRefÞ
(1)
where dAi is a translation parameter mapping animal doses onto an equivalent human dosing scale. Zheng et al.
21
propose placing a tailored log-normal prior on dAi to account for the intrinsic differences between the toxicity of
the drug in animal species Ai 2 fS1; . . . ;SKg and humans. Thus, model parameters hi ¼ ðh1i; h2iÞ describe the
dose–toxicity relationship on an equivalent human dosing scale. In Model (1), dRef is a reference dose invariant
across all dose–toxicity studies, which is often chosen to be the most probable level of the human MTD.
Random-effects distributions are stipulated on the second level of the hierarchical model to enable information
sharing between animal studies of the same species











for Ai 2 fS1; . . . ;SKg. Variances in W reflect between-study heterogeneity within an animal species. A ‘supra-
species’ random effects distribution is introduced to facilitate borrowing of information across different animal











This ‘supra-species’ random-effects distribution accounts for the differences between toxicity parameters in dif-
ferent species which are not addressed by the translation parameters dS1 ; . . . ; dSK .
We now focus on modelling the human toxicity data that will be collected from different human subgroups.
Suppose there are a total of L predefined, non-overlapping human subgroups and one trial only is performed in
each subgroup. To distinguish from the notation used for animal studies, we let ‘ ¼ 1; . . . ;L index the new human
trials wherein doses in D‘ ¼ fd‘1; . . . ; d‘J‘ ; d‘t1  d‘t2 for 1  t1  t2  J‘g are to be evaluated, and let c‘ ¼
ðc1‘; c2‘Þ be the counterpart of hi. That is, c‘ underpins the dose–toxicity relationship in human subgroup ‘.
Model (1) is also applicable to describe the human toxicity data, only that we will set the animal-to-human
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translation parameter dAi ¼ 1 and introduce a subgroup-specific parameter denoted by ‘ for subgroup ‘. For a
phase I clinical trial ‘ ¼ 1; . . . ;L, the human toxicity data can be described by
r‘jjp‘j; n‘jBinomialðp‘j; n‘jÞ; for j ¼ 1; . . . ; J‘;
logitðp‘jÞ ¼ c1‘ þ expðc2‘Þlogð‘d‘j=dRefÞ
(4)
where dRef is the same reference dose used in Model (1) and ‘ adjusts for the differences in toxicity arising from
the intrinsic and/or extrinsic factors across human subgroups. In particular, this parameterisation maps the
‘average’ human dosing scale to the dose–toxicity profile of a particular subgroup. We regard each ‘ as a
random variable, on which we place a truncated normal prior distribution centred at 1 with variance 2‘ for
positive real numbers only, due to the use of a logrithm transformation of the scaled doses.
Here, instead of the log-normal priors which we specify for the animal-to-human translation parameters, we
consider priors with a mode of 1 for ‘: it is reasonable to assume that dose–toxicity data collected from each
human subgroup are on the ‘average’ human dosing scale already. The cases, 0 < ‘ < 1 and ‘ > 1, correspond
to scenarios that the drug (at the same dose) is less or more toxic in subgroup ‘ than on average in humans,
respectively. To ensure symmetry about the mode of 1, these normal priors are truncated to fall within (0, 2);
formally, these are Nð1; 2‘ ÞIð0  ‘  2Þ, with I(a) being the indicator function that I(a)¼ 1 if a is true. For
example, one could place a truncated normal prior Nð1; 0:2552ÞIð0  ‘  2Þ on each ‘. Under this choice, 95%
prior probability mass is concentrated on the interval [0.5, 1.5], meaning that the region-specific MTDs, if
divergent, have less than 0.5-fold change between one another. The variance 2‘ could be increased if even
larger differences in toxicity across regions are considered plausible.
For simplicity, we assumed that one trial only had been undertaken per human subgroup. Following
Neuenschwander et al.,16 our model accommodates two exchangeability scenarios, along with one non-exchange-
ability scenario, for c1; . . . ; cL, respectively. The former precisely includes, (a) parameters of animal and human
dose–toxicity relationships are exchangeable with each other; and (b) human dose–toxicity parameters are
exchangeable only with those of other human subgroups. For human subgroup ‘ ¼ 1; . . . ;L, we stipulate that
• For k ¼ 1; . . . ;K, with prior probability w‘Sk
c‘jlSk ;WBVNðlSk ;WÞ;
This represents exchangeability between c‘ and the study-specific parameters relating to animal species Sk.













so that c‘ is exchangeable only with the study-specific parameters for other human subgroups. Here, U captures a
combination of between-study and between human subgroup heterogeneity.





so that c‘ is non-exchangeable with any other dose–toxicity parameters.
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The prior probabilities w‘S1 ; . . . ;w‘SK ; w‘H and w‘R need to be pre-specified, before the conduct of a phase I trial
in subgroup ‘. Input from translational scientists or pharmacologists will be invaluable. In particular, stipulating a
large w‘Sk or w‘H reflects a high level of prior confidence in the relevance of data from animal species Sk or in the
bridging assumption. Modelling exercise could also be used as additional evidence to inform expert opinion. For
example, determination of such prior probabilities w‘?S1 ; . . . ;w‘?SK ; w‘?H and w‘?R for a new trial in setup, labelled
by ‘?, could be suggested by the posterior probabilities of exchangeability and non-exchangeability pertaining to
the subgroups ‘ 6¼ ‘? involved in the co-data, as the latter helps our understanding about the overall commonality
(or conversely, heterogeneity) between toxicities in animals and humans.
The second ‘human only’ exchangeability distribution in our model has its own covariance matrix U. This is
because the degree of heterogeneity between study-specific dose–toxicity parameters in humans may be quite
different to the level of heterogeneity between study-specific parameters in animals or the variations across
species, captured by W and R, respectively. When animal data have very limited predictability of the human
toxicity yet the human toxicity data between themselves share considerable commonality, our robust hierarchical
model will lead to large posterior probabilities being attributed to the ðKþ 1Þth ‘human only’ exchangeability
distribution. For additional robustness, the model assigns positive prior probability w‘R to the case that c‘ is not
exchangeable with any other parameter vectors. When the dose–toxicity relationship of a human subgroup
appears to be an outlier, that is, dissimilar to that of any other human subgroup or animal species, the parameters
can be estimated based on their own independent prior BVNðm0‘;R0‘Þ.
We visualise the core of the proposed hierarchical model with a diagram in Figure 1, where ðKþ 1Þ exchange-
ability distributions together with one non-exchangeability distribution are stipulated for each human dose–tox-
icity parameter vector c‘; ‘ ¼ 1; . . . ;L. In this simplified setting, between-subgroup heterogeneity cannot be
disentangled from between-trial heterogeneity. It is possible to expand our model to accommodate multiple
trials per subgroup. Letting i ¼ 1; . . . ;M‘ index a trial in subgroup ‘ ¼ 1; . . . ;L, we may denote the trial-
specific parameter vector by c‘i, and further assume that each set of c‘1; . . . ; c‘n‘ are random samples drawn
from their own ‘human only’ exchangeability distribution, say, BVNðlH‘ ;UÞ. The population means
lH1 ; . . . ; lHL could be assumed as exchangeable to enable sharing of information across the human subgroups.
For robust inferences, the probability of exchangeability would be split to assume (a) c‘ijlSk ;WBVN(lSk ;W) with
probability w‘iSk ; k ¼ 1; . . . ;K, and (b) c‘ijlH‘ ;UBVN(lH‘ ;U) with probability w‘iH‘ . In the meanwhile, non-
exchangeability distribution would remain specific to each parameter vector c‘i, that is, c‘iBVN(m0‘;R0‘) with
probability w‘iR ¼ 1
X
k
w‘iSk  w‘iH‘ for each individual trial i in subgroup ‘.
To complete our Bayesian model, we now specify priors for other parameters. Weakly informative priors are
placed on the hyperparameters of the random effects distributions in Models (3) and (5). The weakly informative
priors used in subsequent sections are chosen so that each human toxicity risk p‘j has a wide 95% prior credible
Figure 1. Diagram for the core of the proposed Bayesian hierarchical model. The solid (dotted) arrow suggests where a full (partial)
exchangeability assumption holds. The possibility of non-exchangeability is enabled per human dose-toxicity parameter vector c‘, as
suggested by the dotted verticle line.
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interval.25 For the ‘supra-species’ population means m ¼ ðm1;m2Þ, we set m1Nðb1; s21Þ and m2Nðb2; s22Þ. The
same normal priors are used for l1H and l2H, respectively. Priors for the variance parameters should reflect
opinion on the degree of between-source heterogeneity. Here, we propose setting
s1HNðz1Þ; s2HNðz2Þ; s3HNðz3Þ; s4HNðz4Þ;
r1HNðc1Þ; r2HNðc2Þ; qUð1; 1Þ; jUð1; 1Þ; gUð1; 1Þ
(6)
where HN(z) denotes a half-normal distribution formed by truncating a normal distribution Nð0; z2Þ to fall within
(0;1). In Section 3 with hypothetical data scenarios, we will give an example of how to specify these hyper priors
for robust inferences. The proposed robust Bayesian hierarchical model can be fitted using Markov chain Monte
Carlo. The OpenBUGS26 code, together with R functions, for the implementation of our Bayesian analysis model
is available through https://github.com/haiyanzheng/phaseI_bridging.
3 Illustrative example
In this section, we apply the robust Bayesian hierarchical model proposed in Section 2 to a hypothetical example
informed by a real trial which aimed to characterise the toxicity profile of GSK3050002,27 an antibody for treating
patients with psoriatic arthritis. The original trial enrolled a total of 49 human subjects exclusively in the United
Kingdom. For illustration, we assume that two hypothetical phase I trials (labelled T 1 and T 2) are to be
performed sequentially in two geographic regions, R1 and R2, respectively, with trial T 1 performed first. The
co-data for trial T 2 thus comprises data from trial T 1 and animal data, where available. The choice of animal
species, animal doses and human doses for our numerical studies are informed by the real GSK phase I clinical
trial. For present purposes, we assume the principal aim of these hypothetical trials is to estimate a region-specific
MTD, defined as the dose associated with DLT risk of 25%.
3.1 Hypothetical preclinical data and predictive priors for human DLT risks
According to the protocol of GSK3050002,28 preclinical toxicity studies were performed in monkeys and rats.
Moreover, monkeys were thought to be the most relevant animal species for predicting toxicity in humans. In the
two real monkey studies, doses 1, 10, 30, 100mg/kg were tested on 4–12 monkeys per dose group. From the trial
protocol, it was not possible to identify what dose levels were used in rats, nor the exact number of rats treated,
nor the number of toxicities observed. We therefore simulate plausible animal datasets based on the limited
information available, and use these simulated data to obtain predictive priors for the human DLT risk at
doses contained in the set D‘ ¼ f0:1; 0:5; 1; 5; 10; 20g mg/kg, which will be evaluated in trials T 1 and T 2. The
simulated animal data are represented in Figure S1 of the Web-based Supplementary Materials.
Throughout, we set dRef ¼ 5mg/kg and use the priors as follows. Let l1H;m1Nð1:099; 1:982Þ and
l2H;m2Nð0; 0:992Þ; r1HNð1Þ and r2HNð0:5Þ, and j; gUð1; 1Þ. We assume moderate-to-substantial het-
erogeneity between studies in the same species, and therefore let s1HNð0:5Þ; s2HNð0:25Þ. Furthermore, we
assume small-to-moderate heterogeneity between ethnic subgroups, captured by s3HNð0:25Þ; s4HNð0:125Þ.
Here, we stipulate a half-normal prior HN(z) with smaller z for the slope than that for the intercept, because we
think it is plausible that the slopes of dose–toxicity curves will be more similar than intercepts across studies,
species and subgroups, respectively.29 Following Zheng et al.,21 we set dRatLNð1:820; 0:3232Þ and
dMonkeyLNð1:127; 0:2732Þ to translate the animal data onto a common human scale.
For a robust inference under scenarios of data inconsistency, independent non-exchangeability distributions
BVNðm0‘;R0‘Þ are specified for each c‘. Specifically, we set m01‘Nð1:099; 22Þ and m02‘Nð0; 12Þ, with a zero
correlation between m01‘ and m02‘. By setting w‘Sk ¼ 1 and all other w‘Sk0 ¼ 0; k0 6¼ k, together with w‘H and w‘R as
0, the meta-analytic predictive (MAP) priors for p‘1; . . . ; p‘J‘ are based on the animal data of a single species. For
example, to see how human DLT risks may be predicted by the monkey data, we can fix
w‘Rat ¼ 0; w‘Monkey ¼ 1; w‘H ¼ 0;w‘R ¼ 0. When we set w‘R ¼ 1 and retain the rest as 0, no animal data will be
used, nor are we making an assumption of bridging. Figure 2 summarises the MAP priors by source of infor-
mation. Such summaries are useful to examine whether our Bayesian model can borrow (discount) information
quickly from a particular species, given the data consistency (inconsistency).
As we can see, the rat and monkey data predict 1mg/kg and 5mg/kg as doses highly likely to result in a
human DLT risk close to 25% in a human trial. After translation of the animal doses, rat data are mainly
projected on the low doses of D‘. Predictive priors obtained solely from rat data are thus more diffuse at high
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doses such as 10mg/kg and 20mg/kg, at which the monkey data in contrast have produced predictive priors for
the DLT risks with narrower credible intervals. Patients recruited in regions R1 and R2 are predicted as having
similar DLT risks based on the animal data. This is because for ‘ ¼ 1; 2, we specify the same prior probabilities
w‘Rat; w‘Monkey; w‘H and w‘R, as well as the same truncated normal prior on ‘, have been chosen for each human
trial ‘ at the outset.
We obtain MAP priors for the DLT risk in humans, by allocating prior weights to different animal species on
the basis of their a priori predictability of the human toxicity. For trial T 1, we stipulate w1Rat ¼ 0:2; w1Monkey ¼
0:6; w1H ¼ 0 and w1R ¼ 0:2. No prior probability has been allocated to the exchangeability distribution for
bridging across patient subgroups because trial T 2 has not yet started, meaning that the co-data for T 1 are
exclusively from animal studies. We note this is the Bayesian model proposed by Zheng et al.,21 suitable for
leveraging animal data to one homogeneous patient group. Figure S2 of the Supplementary Materials gives
summaries of the MAP priors that robustly synthesise information across animal species to predict the human
DLT risks. As soon as trial T 2 begins, the ðKþ 1Þth exchangeability component comes into play. For illustration,
we set w2Rat ¼ 0:1; w2Monkey ¼ 0:5; w2H ¼ 0:2 and w2R ¼ 0:2 to leverage both animal data and the T 1 trial
data, the human data from region R1, into trial T 2. During the conduct of trial T 2, the specification for prior
probabilities w1Sk and w1R remain unchanged. In other words, no data from trial T 2 will be leveraged to re-analyse
trial T 1.
We characterise the predictive prior per dose d‘j 2 D‘ by three interval probabilities; specifically, probabilities
that a patient may be (i) underdosed, said to occur if the DLT risk is less than 0.16, (ii) properly dosed, if the DLT
risk fall within the target interval [0.16, 0.33) and (iii) overdosed, if the DLT risk is greater than 0.33.24 In this data
example, we suggest choosing 0.1mg/kg to be the safe starting dose for the first-in-man trial T 1, given
Pðp11 < 0:16jY1; . . . ;Y5Þ ¼ 0:872, where Y1; . . . ;Y5 denote the five hypothetical animal datasets collected from
the rat and monkey studies. The choice of safe starting dose for trial T 2 will be based on both the animal data and
the human toxicity data from region R1 with a similar approach.
It will be helpful to assess the effective sample size (ESS)15 of the predictive priors for each p‘j; j ¼ 1; . . . ; J‘.
Before the conduct of human trials T 1 and T 2, we approximate each marginal predictive prior for the DLT risk per
dose by a Beta(a, b) distribution, for the convenience of calculating the ESS as ðaþ bÞ. The parameters a and b are
determined by matching the first two moments of a Beta(a, b) with the original marginal predictive priors, obtained
based on animal data. Table S1 of the Web-based Supplementary Materials reports the computed ESSs. Basically,
the animal data are equivalent to what would be acquired from 4.5 to 8.2 human subjects treated in each trial.
3.2 Design and conduct of the phase I trials in different patient subgroups
Suppose that the phase I trials T 1 and T 2 are planned to have equal, maximum sample size, say, 24 patients. We
begin by recruiting patients in cohorts of size three to trial T 1. After the toxicity responses have been observed
from the last cohort of trial T 1, trial T 2 begins with the same trial structure. Specifically, the co-data for trial T 2
Figure 2. Summaries about the predictive priors for human toxicity, when using animal data from a single species (Panels A and B) or
no animal data at all yet with a bridging assumption (Panel C) or without (Panel D). Medians together with 95% credible intervals of
the marginal predictive priors are plotted.
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are from both the animal studies and trial T 1. We use h‘ to index the cohort number of trial T ‘; so Yðh‘ÞT 1 or Y
ðh‘Þ
T 2
denote the human toxicity data accrued in cohorts 1; . . . ; h‘ of trial T 1 or T 2, respectively.
Recall that we have estimated dose 0.1mg/kg as a suitable starting dose for patients in cohort h‘ ¼ 1 of trial T 1.
For the subsequent patient cohorts, a dose will be recommended according to the criterion
d̂
ðh1Þ
T 1 ¼ maxfd1j 2 D1 : Pðp1j  0:33jY1; . . . ;Y5;Y
ðh11Þ
T 1 Þ  0:25g for h1  2 (7)
Phase I trials will be terminated either after completion of treatment for all 24 patients, or for safety if for any
dose (including the lowest dose) the posterior risk of overdosing is too high. When the complete data from trial
T 1, denoted by YT 1 , are available, we start trial T 2 with dose
d̂
ðh2¼1Þ




T 2 ¼ maxfd2j 2 D2 : Pðp2j  0:33jY1; . . . ;Y5;YT 1 ;Y
ðh21Þ
T 2 Þ  0:25g for h2  2 (8)
to be recommended to patients in the subsequent cohorts. To prevent escalating doses too rapidly, additional
constraints such as ‘never skipping a dose during escalation’ may be applied in practice. This means, in our
illustrative example, one cannot skip dose 0.5mg/kg to recommend 1mg/kg for patients in cohort 2 of trial T 1,
even if the first three doses all comply with criteria (7) and (8).
Figure 3 shows two simulated realisations of trials T 1 and T 2. These data examples were simulated under
different scenarios for the human dose–toxicity relationship. Subfigure (i) considers a scenario of divergent dose–
toxicity relationships in regions R1 and R2, while subfigure (ii) assumes the two relationships are consistent.
Figure 3 verifies that the choice of a safe starting dose in trial T 2 relies on the toxicity data from trial T 1. Reading
Figure 3(i) together with Figure 2, there seems to be no relevant animal data for the first-in-man trial T 1 in
scenario (i); moreover, considerable heterogeneity exists between trials T 1 and T 2. Despite this, the proposed
Bayesian approach allows the irrelevant external data to be discounted quickly in trials T 1 and T 2, leading to
declaration of doses 20mg/kg and 5mg/kg as the region-specific MTDs.
On the completion of trial T 1, we can evaluate the posterior ESSs of the human DLT risks before the start of
trial T 2. Table 1 lists the ESSs of the marginal posteriors for the DLT risks, or say, the MAP priors for
p21; . . . ; p2J2 , given data from trial T 1 in scenarios (i) and (ii). As we observe, even when there exists fairly rich
data from region R1, the MAP priors for p21; . . . ; p2J2 are unlikely to dominate the estimation of MTD specific to
region R2.
4 Simulation study
In this section, we compare the operating characteristics of phase I dose-escalation trials, conducted using the
proposed Bayesian hierarchical model or an alternative. The analysis models we consider are as follows:
Figure 3. Trial trajectory of hypothetical phase I trials performed in two geographic regions, in which trial data were simulated from
(i) a divergent scenario and (ii) a consistent scenario, respectively.
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• Model A is the proposed Bayesian model leveraging co-data from multiple sources;
• Model B discards animal data and assumes human parameter vectors c1 and c2 fully exchangeable; specifically,
w‘Rat ¼ w‘Monkey ¼ 0; w‘H ¼ 1 and w‘R ¼ 0;
• Model C analyses trials T 1 and T 2 separately, without leveraging any animal data; specifically, w‘Rat ¼
w‘Monkey ¼ w‘H ¼ 0 and w‘R ¼ 1;
• Model D leverages animal data for trials T 1 and T 2 but permits no borrowing across human subgroups;
specifically, w‘Rat ¼ 0:2; w‘Monkey ¼ 0:6; w‘H ¼ 0 and w‘R ¼ 0:2;
• Model E analyses trial T 1 without using any co-data, and trial T 2 pooling data only from T 1.
The prior specifications for Model A remain unchanged from Section 3.1. All the simulated T 1 trials, regardless
of the analysis model, begin with the lowest dose 0.1mg/kg. Simulated T 2 trials begin with dose 0.1mg/kg, when
implementing Models C and D. However, the choice of a safe starting dose for T 2 is conditional on both
animal data and data from T 1 trial data when using analysis Model A, and solely on T 1 trial data when using
Model B or E. In these settings, we select as the starting dose for trial T 2 the highest dose d2j? that complies with
Pðp2j? < 0:16jY1; . . . ;Y5;YT 1Þ > 0:85 for Model A, or Pðp2j? < 0:16jYT 1Þ > 0:85 for Model B or E. Model D is
essentially to apply the model of Zheng et al.21 to trials T 1 and T 2, respectively. We note that Model A simplifies
to Model D if setting w‘H ¼ 0 while the other prior probabilities of exchangeability and non-exchangeability the
same across subgroups ‘.
Each simulated phase I trial is performed in an adaptive manner: interim dose recommendations are made
according to criteria (7) and (8) for trials T 1 and T 2, respectively. Given the true probability of toxicity per human
dose listed in Table 2, we simulate human DLT outcomes from a binary distribution. We evaluate the operating
characteristics under the six scenarios, comprising cases where there are conflicts across data sources, and cases
where parameters in different subgroups are exchangeable. Scenarios 1 and 6 represent two extremes. Only
simulated trials where all 24 patients are treated and their toxicity outcomes observed will lead to a declaration
of a region-specific MTD. At the end of a completed trial in region R‘, we declare the MTD as the dose satisfying
d̂‘M ¼ arg min
d‘j2D‘ 0
j~p‘j  0:25j
where ~p‘j denotes the posterior median DLT risk at dose d‘j, and D‘0  D‘ contains all the doses that were used to
treat patients in trial T ‘, and satisfy our overdose criterion. Simulations were run in R (version 3.4.4)30 using the
package R2OpenBUGS31 based on two parallel chains, each contributing 15,000 MCMC samples and sacrificing
the first 5000 iterations as burn-in.
For each toxicity scenario, we simulated 1000 pairs of adaptive phase I dose-escalation trials in regions R1 and
R2. In what follows, results are summarised by region. Averaging across the simulated phase I trials, we report the
Table 1. Effective sample sizes of the marginal predictive posteriors (priors) for the DLTrisk per dose, on the completion of trial T 1
(start of trial T 2), given the T 1 trial data simulated from (i) a divergent scenario and (ii) a consistent scenario, respectively
Trial T 1 Trial T 2
d11 d12 d13 d14 d15 d16 d21 d22 d23 d24 d25 d26
0.1 0.5 1 5 10 20 0.1 0.5 1 5 10 20
Sc (i)
Posterior/Prior means 0.027 0.045 0.058 0.107 0.144 0.199 0.070 0.114 0.143 0.271 0.357 0.434
Posterior/Prior std dev. 0.031 0.042 0.048 0.068 0.079 0.105 0.110 0.141 0.158 0.222 0.260 0.280
ESS 26.3 23.4 22.7 19.7 18.8 13.5 4.3 4.1 4.0 3.0 2.4 2.1
a 0.7 1.1 1.3 2.1 2.7 2.7 0.3 0.5 0.6 0.8 0.9 0.9
b 25.6 22.3 21.4 17.6 16.1 10.8 4.0 3.6 3.4 2.2 1.5 1.2
Sc (ii)
Posterior/Prior means 0.046 0.090 0.126 0.316 0.420 0.510 0.073 0.121 0.154 0.298 0.395 0.483
Posterior/Prior std dev. 0.043 0.058 0.064 0.156 0.210 0.233 0.111 0.138 0.153 0.206 0.242 0.259
ESS 23.0 23.4 25.8 8.0 4.7 3.7 4.5 4.6 4.6 4.0 3.1 2.7
a 1.1 2.1 3.3 2.5 2.0 1.9 0.3 0.6 0.7 1.2 1.2 1.3
b 21.9 21.3 22.5 5.5 2.7 1.8 4.2 4.0 3.9 2.8 1.9 1.4
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percentage of trials that were stopped early for safety, and percentage of trials that declared a region-specific
MTD. In addition, we reported the average number of patients allocated to each dose.
Complete results from the simulation study can be found in Table S2 of the Supplementary Materials, and
comparisons between Models A, C and E are presented in Figure S3. Here, we focus on comparing the operating
characteristics of trials driven by Models A, B and D shown in Figure 4. We see that Model A outperforms the
alternative analysis models across nearly all the simulation scenarios. In scenarios 1 and 2, where animal data are
highly predictive of human DLT risks, Models A and D which leverage animal data lead to a higher percentage of
correct selection (PCS) and a higher proportion of patients allocated to tolerable doses with DLT risks in the
range [0.16, 0.33) than Model B. Comparing Models A and D, allowing for information sharing across patient
subgroups leads to an increase in the PCS in trial T 2 from 16% to 45% in scenario 1, where DLT risks are
identical across regions. Borrowing across human subgroups offers smaller but still meaningful gains in PCS in
scenarios 2 and 3, when DLT risks are similar, but not identical, in regions R1 and R2. Due to the ‘no-skipping-
of-dose’ restriction and a small sample size, it is challenging in scenario 4 to declare doses 20 and 10mg/kg as
region-specific MTDs in trials T 1 and T 2, respectively. Nevertheless, trials performed using Model A have the
highest PCS in regions R1 and R2. In particular, comparing Model A with D in scenario 4, we see an increase of
25.3% in PCS and, on average, about six more patients treated at the true MTD in trial T 2.
In scenario 5, all the Bayesian analysis models (A–E) limit the exposure of patients to overly toxic doses, say,
doses with a DLT risk exceeding 50%. Due to the use of animal data, Models A and D tend to treat more patients
than Model B with doses 0.5 and 1mg/kg, which have human DLT risks exceeding 33%. However, the average
number of patients experiencing a DLT is not substantially higher than the number under Model B. Scenario 6
represents the case where the bridging assumption is incorrect. Comparing trial operating characteristics under
Model A with those under Models C and D, we find trials driven by Model A allocate 6–7 more patients to dose
1mg/kg in trial T 2 and more often incorrectly select this dose as the MTD forR2. However, the PCS in region R2
remains comparable across analysis models (33.3% for Model A and 37.2% for Model D).
In scenarios 1–3, Model B assigned more patients in trial T 1 to dose 1mg/kg than the true MTD 5mg/kg, due
to the stated ‘no-skipping’ dose-escalation constraint and our rule for defining the MTD: only administered doses
are eligible to be selected as a MTD. Consequently, more trials concluded selecting a safer dose as the MTD. In
scenarios 3 and 4, Model B experienced increasing difficulty distinguishing between region-specific MTDs, par-
ticularly in trial T 2 when the true MTD lies towards the top end of D2 and when differences between human risks
in different regions are relatively small. Indeed, the assumption of full exchangeability led to excessive sharing of
information between the two phase I clinical trials. In scenario 5, trials in R1 conducted using Model B were more
likely to be stopped early for safety. Models A and B gave divergent operating characteristics in scenario 6. As
Model B tends to underestimate the toxicity in region R1 in such a scenario, excessive borrowing of information
across regions led to more trials in R2 stopped early than under Models A and D.
Referring to the Supplementary Materials, we can draw comparisons between the operating characteristics of
dose-escalation procedures driven by Model A versus Models C and E. Models C and E can be regarded as
extremes, with either permit no borrowing at all or complete pooling of human data across regions. The improved
operating characteristics when comparing Models A and C should be interpreted as a mixture of the benefit from
using both animal data and an appropriate bridging strategy. We have also compared Models A–E with respect to
the posterior median estimates of the human DLT risks in each region, dose–toxicity relationship in each human
Table 2. Simulation scenarios for the true probability of toxicity in humans for the phase I trials T 1 and T 2. The figure in bold
indicates the target dose closest to the true MTD in each region.
Trial T 1 Trial T 2
d11 d12 d13 d14 d15 d16 d21 d22 d23 d24 d25 d26
0.1 0.5 1 5 10 20 0.1 0.5 1 5 10 20
Scenario 1 0.01 0.03 0.10 0.25 0.34 0.47 0.01 0.03 0.10 0.25 0.34 0.47
Scenario 2 0.01 0.03 0.10 0.25 0.34 0.47 0.05 0.12 0.25 0.37 0.50 0.60
Scenario 3 0.01 0.03 0.10 0.25 0.34 0.47 0.01 0.03 0.07 0.15 0.25 0.37
Scenario 4 0.01 0.03 0.05 0.08 0.15 0.25 0.02 0.05 0.07 0.12 0.25 0.36
Scenario 5 0.25 0.34 0.47 0.55 0.65 0.75 0.40 0.50 0.60 0.70 0.80 0.90
Scenario 6 0.01 0.03 0.05 0.08 0.15 0.25 0.10 0.25 0.36 0.50 0.60 0.68
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subgroup. Figure S4 of the Supplementary Materials show that Model A outperforms the others, providing very
satisfactory characterisation of the association on the termination of a phase I clinical trial. We additionally ran
simulations for a robust version of Model B with w‘R ¼ 0:20. Conclusions are similar with those written in
Neuenschwander et al.16 and Zheng et al.21 on the advantage of including a robust weakly informative distribu-
tion, and thus will not be repeated in this paper.
We introduced bridging parameters 1; 2 into the human dose–toxicity models. Model A maps animal data
onto the equivalent human dosing scale for the incorporation into human trials T 1 and T 2. With inclusion of a
random ‘ after setting dAi ¼ 1 for the human trials, the posterior distribution of the bridging parameters captures
whether animal data over- or under-predicted the DLT risk in a specific human subgroup. See Figure 5 for the
boxplots of Model A in scenario 4, where rat and monkey data lead to under-estimation of human DLT risks. We
observe the posterior means of 1 and 2 are shifted downwards from the prior mean of 1. When the posterior
mean of ‘ is shifted to take a value larger than 1, it suggests animal data are likely to have overestimated the
human DLT risks; see, for example, scenario 2 for trial T 2. In scenario 5, many simulated trials are stopped early
Figure 4. Operating characteristics of the adaptive phase I dose-escalation trials in regionsR1 andR2, conducted and analysed using
Models A, B and D. The vertical black solid (dotted) line indicates the true MTD in the phase I trial T 1 (trial T 2) in each simulation
scenario.
Zheng et al. 1067
for safety, and since ‘ is only estimated for a completed trial, we exclude results for this scenario in Figure 5. In
contrast, the parameter ‘ embedded in Model B exclusively addresses the intrinsic differences arising from
ethnicity between patient subgroups. Within the same scenario, say, scenarios 1 and 3 where the bridging assump-
tion is correct, 1 and 2 take values centring around 1 (the normal prior mean). When the drug is more toxic in
region R1 than R2, the posterior means of 2 tend to be larger; for example, see results for scenarios 2 and 6.
Additional simulations were performed to support future application of the proposed Bayesian hierarchical
model. In particular, we evaluated the impact of prior probabilities of exchangeability and non-exchangeability,
i.e. w‘S1 ; . . . ;w‘SK ;w‘R, for ‘ ¼ 1; 2 (Section C of the Web-based Supplementary Materials). We find that a large
w‘Sk means the MAP prior would likely be dominated by the corresponding BVNðlSk ;WÞ; k ¼ 1; . . . ;K, and
therefore could lead to much enhanced operating characteristics in scenarios of prior-data consistency.
Whereas, this is at the cost of increased difficulty for down-weighting any animal data in scenarios of prior-
data inconsistency. Additionally, we compare the proposed methods to the bridging CRM in Liu et al.12 (Section
D of the Supplementary Materials). As expected, the inclusion of animal data in the escalation procedure yields
improved performance when such information is relevant.
5 Discussion
Bridging studies have received considerable interest,32 as fewer resources may be needed to demonstrate drug
behaviours by using relevant data from other subgroups, compared with the approach of establishing an inde-
pendent, complete package of clinical drug development. Statistical methodology to extrapolate across geographic
regions has been proposed mainly in the context of phase II and phase III clinical trials.33–36 Much less has been
written on phase I clinical trials, where different metrics are used to evaluate trial efficiency and estimation
accuracy.
In this paper, we seek to improve decision making in a phase I bridging study, by leveraging not only the trial
data on an original subgroup/region for drug registration, but also preclinical animal data. The novelty of the
proposed methodology is relating to sensible constellations of parameter vectors. Technically speaking, the hier-
archy of the proposed model is constructed by placing the human dose–toxicity parameter vectors c1; . . . ; cL at the
same level as the standardised, study-specific, animal parameter vectors h1; . . . ; hM; for local robust inferences
about each c‘; ‘ ¼ 1; . . . ;L, we split the full probability of exchangeability into fractions w‘S1 ; . . . ;w‘SK ;w‘H and
w‘R, which sum up to 1. Moreover, independent weakly-informative priors BVNðm0‘;R0‘Þ are placed on
Figure 5. Boxplots that depict the posterior means of the region parameter ‘ estimated by the end of completed trials, designed
using Model A or Model B. The horizontal black line represents the prior mean of ‘.
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c1; . . . ; cL, respectively, for the possibility of non-exchangeability. Gains in operating characteristics can therefore
be attributed to the incorporation of consistent animal data or data from the original geographic region, or both.
In our simulation study, we use the prior probabilities w‘S1 ; . . . ;w‘SK ;w‘H and w‘R that have been specified
individually for subgroups ‘ ¼ 1; 2. Nonetheless, it is viable to tightly associate the prior probabilities for the
bridging trial T 2 with the posterior probabilities obtained by the end of the trial T 1. Such specification has pros
and cons. As noted by one anonymous reviewer, this could facilitate the understanding towards (dis)similarity
between toxicity profiles in animals and humans. An unfavourable scenario, however, could easily be envisaged.
That is, the maximally attainable operating characteristics could be limited, when the toxicity in humans is very
distinct across regions R1 and R2. Future practitioners may choose these prior probabilities on a case-by-case
basis, although extensive simulations presented in this paper have assured a robust inference about the region-
specific MTDs.
We note that the proposed methodology has wider applications. For example, there may be a need to design
phase I dose-escalation trials in subgroups defined by clinical or genetical characteristics which could potentially
modify the therapeutic effect of the drug.37 Based on our Bayesian model, information from patient subgroups
with similar safety profiles can be leveraged. There is no restriction on the number of studies that will be run in the
new patient subgroups, nor on the number of subgroups to provide the co-data. When a large number of
subgroups are involved, estimate of parameters that represent the between-trial heterogeneity (specifically,
s3; s4) tends to be more accurate. It would therefore better determine the degree of borrowing across human
trials T 1; . . . ; T L.
This paper has focused on the design of bridging studies to estimate the MTD in a new geographic region or
human subgroup of a previously studied disease indication, although the approach can also be used for other
settings. Future work could consider extending the proposed hierarchical model to accommodate the case of
bridging across subgroups in related disease indications, when distinct endpoints, different dosing schedules or
formulations, etc. might be necessary. The research question is highly relevant within the paradigm for precision
medicine. A new class of efficient approaches, known as basket trials,38 have emerged, where the same treatment is
tested in potentially heterogeneous patient subgroups (often defined by genetic characteristics). Robust hierar-
chical models have been considered for borrowing of information.39,40 The proposed methodology can potentially
be used to analyse phase I oncology basket trials, where multiple cancer subtypes are studied under a master
protocol.41 It is conceptually similar to the proposal by Neuenschwander et al.39: prior probabilities of exchange-
ability and non-exchangeability are assigned independently to each vector of subgroup-specific dose–toxicity
model parameters. Our Bayesian model allows co-data to contribute towards formulating the exchangeability
distributions so as to discuss borrowing of information from specific sources. Independent non-exchangeability
distributions ensure we obtain the robust estimates of the dose–toxicity model parameters underpinning extreme
subgroups. Improving statistical inferences for extreme subgroups, which could be similar amongst themselves, is
outside of the scope of the present research. This is an area for future research, with related investigation under-
taken in the context of phase II basket trials to enable information sharing based on distributional discrepancy
between model parameters for therapeutic effects.42
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